

# Contents

Preface	7
<b>Part I</b>	<b>9</b>
Section I Background to the TRIPS Agreement	9
1.1 GATT and Its Transition to the WTO	10
1.2 TRIPS Agreement	11
Section II: Public Health Safeguards in the TRIPS Agreement	16
2.1 Flexibilities in TRIPS Agreement	16
2.2 Use of Flexibilities to Safeguard Public Health	18
2.3 Doha Declaration on TRIPS and Public Health	19
2.4 Experiences in the Use of Flexibilities under the TRIPS Agreement	22
2.4.1 Use of Compulsory License	22
2.4.2 Determining Royalty Rights in Case of a Compulsory License	23
Section III Emerging Issues in Intellectual Property Protection and Access to Medicines	27
3.1 Free Trade Agreements and Patent Protection	27
3.2 Data Protection and Data Exclusivity	28
Section IV Intellectual Property Rights and Access to Medicines	32
Section V Implementing Public Health Safeguards under Indian the Patents Act	38
5.1 Options in the Indian Patents Act to Ensure Access to Medicines	38
5.1.1 Government Use and Non-Commercial Use	39
5.1.2 License for local manufacture of generics	42
5.2 Options in Indian Patents Act for Imports	44
5.3 Exports of Drugs from India	44
5.4 Restrictions on Patentability	47
5.5 Pre- and Post-grant Opposition to Patents	53
5..6 Continued Manufacture of Drugs with applications in the "mailbox"	54

5.7	Use of Patented Subject Matter for Research	55
Section VI	Areas of Concern Related to Public Health in Indian Patents Act	56
6.1	Major Areas of Concern regarding Compulsory Licensing Provisions	56
6.2	Patentability: Finding ways to restrict Patents	59
6.3	Pre-grant Opposition	60
6.4	Appeal in Case of CL for National Emergency	61
6.5	Revocation for Non-Working	31
6.6	Rights of Patent Applicants after Publication:	61
6.7	Publication of Application	62
6.8	Issues Pending After Patent Amendment (Third) Act	62
6.8.1	The definition of a pharmaceutical substance	62
6.8.2	Patenting of Micro organisms	63
6.9	Effect on Drug Prices and Availability	64
Section VII:	Role of the Ministry of Health	66
7.1	Prior Consent of Ministry of Health in Promoting Access	66
7.2	Determining When to Issue Compulsory License for Government Use	67
7.3	Tracking Patents Issued on Medicines and other Medical Devices	68
7.4	Capacity Building to Address Issues Related to Patents and Access to Medicines	68
Annexure:	Provisions in Indian Patent Act that have relevance for Public Health	69
<b>Part II</b>		<b>107</b>
	Analysis of “Mailbox” Applications with special reference to Public Health	109
Annexure I	Drugs Approved in India Between 1995 and 2006	109
annexure II	Patent Expiry Date of Drugs	127
Annexure III	Process Patents Granted on Pharmaceuticals since 2005	131
Annexure IV	Product Patents and Patents for Combinations, dosage forms, treatment methods, etc. (process and products)	167
Annexure V	Patents for Medical Devices/ Instruments/	

	Prostheses, etc.	180
Annexure VI	Trivial/Unusual Patents Granted (not limited to pharmaceuticals or health related)	188
Annexure VII	Analysis of Patent Applications Filed by Ranbaxy Between 1995 and 2004	195
Annexure VIII	Analysis of patent Applications Filed around Lamivudine	201